Generic Firms Required to Disclose Supply Info from June after Pilot Rollout of Company Indicators
To read the full story
Related Article
- MHLW to Disclose Company Names under Generic Index Rule Possibly in FY2026
December 19, 2024
- Discussions on Generic Company Indices Make Headway towards Full Rollout in Next Revision
December 13, 2024
- Chuikyo Supports Full Rollout of Company Indices for Generics Manufacturers
November 7, 2024
- Over 60% of Generic Firms Carry Jointly Developed Products, 98% of Espha Drugs Fall into This Category
July 3, 2024
- Japan Finalizes Generic Info Disclosure Guidelines for Company Indicator Rule
April 2, 2024
- Disclosure Guidelines on Generic Supply Info Up for Public Comments
March 13, 2024
REGULATORY
- MHLW Not Yet Able to Examine Letters of Protest by US Lobbies: Minister
February 13, 2025
- More Flu Drugs Returned than Supplied in Japan: Final Week of January
February 12, 2025
- PMDA to Modify Onsite GCP Inspections Based on Facility Track Records
February 10, 2025
- PMDA Reviewing Safety Risks for Immune Checkpoint Inhibitors, CAR-Ts
February 10, 2025
- Shionogi’s ADHD Game Therapy, CureApp’s Alcoholism App in Line for Approval
February 7, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…